PF-Atlas › Clinical Trials › BEAM-AATD

Beam Therapeutics Base Editing for Alpha-1 Antitrypsin Deficiency

BEAM-302 · CRISPR Base Editing · Phase 1

Registry ID
BEAM-AATD
Phase
Phase 1
Status
Recruiting
Drug / intervention
BEAM-302
Mechanism
CRISPR Base Editing
Sponsor
Beam Therapeutics
Start
2024-06

About this trial

BEAM-302 is evaluated in BEAM-AATD, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Beam Therapeutics, targeting crispr base editing. Current status: Recruiting.

View BEAM-AATD on ClinicalTrials.gov →

Explore related

All BEAM-302 trialsCRISPR Base Editing mechanismAll IPF trials
Medical disclaimer. This page summarizes public trial data for BEAM-AATD for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.